ANI Pharmaceuticals Inc expected to post earnings of $1.00 a share - Earnings Preview

ANI Pharmaceuticals

08/05/2024 14:52

* ANI Pharmaceuticals Inc  ANIP.OQ   ANIP.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 10 for
the period ending March 31 2024
    * The Baudette Minnesota-based  company is expected to
report a
18.0% increase in revenue to $126.028 million from $106.79
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for ANI Pharmaceuticals Inc
is for
earnings of $1.00 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 2.4%
in the last three months. ​
    * Wall Street's median 12-month price target for ANI
Pharmaceuticals Inc is $80.00​, above​ its last closing price
of $66.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   0.85        0.86       1.00      Beat    17
 Jan. 1 0001   0.85        0.84       1.27      Beat    50.6
 Jan. 1 0001   0.67        0.68       1.28      Beat    88.9​
 Jan. 1 0001   0.36        0.35       1.17      Beat    231.9
 ​​Dec.        0.66        0.67       0.76      Beat    13.1
 31 2022                                                
 Sep. 30 2022  0.55                   0.64              15.8​
 Jun. 30 2022  0.22                   0.13              
 Jan. 1 0001   0.10        0.09       -0.12     Missed  -228.6
 This summary was machine generated May 8 at 13:51 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)